Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2017-10-02 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a clinical study update but does not contain detailed financial statements or comprehensive financial analysis. The document length is short (1970 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2017-10-02 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about an upcoming announcement of top-line results from a Phase II study. The document is short (1975 characters) and primarily serves as a regulatory filing to disclose material information to the market. It does not contain detailed financial statements or comprehensive report content. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are periodic reports for foreign issuers that do not fit into other specific categories like Annual Reports or Interim Reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-09-28 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a patent allowance but does not contain financial statements or detailed financial data. The document length is short (1990 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2017-09-18 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at a healthcare conference. Form 6-K is used by foreign private issuers to report material information between annual reports (Form 20-F or 40-F). The document is short (1945 characters) and primarily serves as a regulatory update with an attached press release, not a full financial report or detailed presentation. It does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2017-09-18 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about the initiation of promotion of a pharmaceutical product in the U.S. The document is short (1971 characters) and primarily serves as a regulatory announcement rather than a detailed financial report or earnings release. Form 6-K filings are typically used for current reports by foreign private issuers and often contain press releases or other material information. This does not fit the definitions of Annual Report, Earnings Release, or other detailed financial filings. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement and press release submission to the SEC.
2017-09-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the company's presentation at a conference. The document is short (1964 characters) and primarily serves as an announcement of an event rather than containing detailed financial data or comprehensive reports. Form 6-K filings typically serve as periodic reports for foreign issuers to disclose material information. Given the nature and length of the document, it does not contain full financial statements or detailed management discussion. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-09-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.